European Heart Journal Advance Access originally published online on April 27, 2006
European Heart Journal 2006 27(16):1908-1920; doi:10.1093/eurheartj/ehi875
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Evidence-based use of levosimendan in different clinical settings
1 Division of Cardiology, European Hospital, Rome, Italy
2 Cardiovascular Medicine Section, Boston University Medical Center, Boston, MA, USA
3 Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland
4 Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California, San Francisco, CA, USA
5 Division of Cardiology, Northwestern University, Feinberg School of Medicine Galter 10-240, 201 E. Huron Street, Chicago, IL 60611, USA
Received 10 January 2006; revised 15 March 2006; accepted 23 March 2006; online publish-ahead-of-print 27 April 2006.
* Corresponding author. Tel: +1 312 6950051; fax: +1 312 6951434. E-mail address: m-gheorghiade{at}northwestern.edu
Levosimendan is a new calcium sensitizer and K-ATP channel opener. Compared with other inodilators, it improves myocardial contractility without increasing oxygen requirements and induces peripheral and coronary vasodilation with a potential anti-stunning, anti-ischaemic effect. The documentation regarding levosimendan is one of the largest ever on the safety and efficacy of a new pharmacological agent in acute heart failure syndromes. Recent experiences in small-scale studies and randomized clinical trials have led to greater interest in the use of this drug for the support of impaired cardiac function also in patients with ischaemic heart disease and cardiogenic or septic shock. It is also demonstrated that this drug could be used as bridge therapy for the peri-operative phase of cardiac surgery in both adult and paediatric populations. This review summarizes the evidence from published scientific literature regarding the use of levosimendan in various clinical settings.
Key Words: Levosimendan • Calcium sensitizers • Inotropic agents • Heart failure • Cardiac surgery • Ischaemic heart disease • Cardiogenic shock
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. A. Segreti, K. C. Marsh, J. S. Polakowski, and R. M. Fryer Evoked Changes in Cardiovascular Function in Rats by Infusion of Levosimendan, OR-1896 [(R)-N-(4-(4-Methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide], OR-1855 [(R)-6-(4-Aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one], Dobutamine, and Milrinone: Comparative Effects on Peripheral Resistance, Cardiac Output, dP/dt, Pulse Rate, and Blood Pressure J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 331 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Herget-Rosenthal, F. Saner, and L. S. Chawla Approach to Hemodynamic Shock and Vasopressors Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 546 - 553. [Full Text] [PDF]
|
|
|
|
 |
|
 P. N. Banfor, L. C. Preusser, T. J. Campbell, K. C. Marsh, J. S. Polakowski, G. A. Reinhart, B. F. Cox, and R. M. Fryer Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H238 - H248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gheorghiade, M. A. Konstam, J. C. Burnett Jr, L. Grinfeld, A. P. Maggioni, K. Swedberg, J. E. Udelson, F. Zannad, T. Cook, J. Ouyang, et al. Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart Failure: The EVEREST Clinical Status Trials JAMA, March 28, 2007; 297(12): 1332 - 1343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Agewall and D. Atar Levosimendan: Perpetuum mobile? Eur. Heart J., February 5, 2007; (2007) ehl487v1. [Full Text] [PDF]
|
|